Drug intelligence / Profile preview

NTX8090

Development stage: Preclinical
Lead developer: Nectin Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

NTX8090 is an antibody-drug conjugate (ADC) being developed by Nectin Therapeutics. It specifically targets the poliovirus receptor (PVR, also known as CD155), a protein that is frequently overexpressed in various solid tumors and plays a significant role in tumor immune evasion by interacting with inhibitory receptors on immune cells. By utilizing an ADC modality, NTX8090 is designed to deliver a cytotoxic payload directly to PVR-expressing malignant cells, with a particular focus on treating "cold" tumors—malignancies that are typically resistant to standard immunotherapies. The program is currently in the IND-enabling stage of development for the treatment of treatment-resistant solid malignancies.

Targets

PVR

Beyond the preview

Go deeper on NTX8090.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTX8090.

Explore the full profile